Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Japan-based pharmaceutical company Daiichi Sankyo has established its own subsidiary in Ireland. As part of this effort, 14 employees from the cardiometabolic sales force at Merck Serono are being transferred to Daiichi Sankyo.
Subscribe to our email newsletter
The company will be called Daiichi Sankyo Ireland and be headquartered in Dublin. In addition to the osteoporosis medication Evista, Daiichi Sankyo Ireland will market the anti-hypertensive product Cardicor, for the treatment of cardiac insufficiency, as well as Emcor for the treatment of hypertension and angina pectoris.
Daiichi Sankyo Ireland will also sell the diabetes drug Glucophage as part of a co-promotion agreement with Merck Serono.
Reinhard Bauer, CEO of Daiichi Sankyo Europe, said: “Entering the market in Ireland is an important step in our effort to expand our European presence. Over the middle term, the range of products is to grow considerably, particularly in terms of cardiovascular medications emerging from the company’s own research pipeline.”